case_images: PMC9515502_01
case_images: Lung CT images: (A) before dacomitinib administration; (B) 37 days after dacomitinib administration; (C) 50 days after dacomitinib termination; and (D) 95 days after afatinib administration.
case_images: fonc-12-979462-g001.jpg
case_images: PMC9515502_01_fonc-12-979462-g001.jpg
case_images: f1
case_images: A 40 x 33 x 46 mm mass in the paramediastinal of the upper lobe of the left lung is shown in  Figure 1A . As shown in  Figure 1B , the tumor size was significantly reduced compared with pre-treatment ( Figure 1A ). Fifty days after dacomitinib termination, a lung CT image showed an increased tumor size ( Figure 1C ), and the patient received afatinib 30 mg daily the next day. 34 and 95 days after afatinib administration, lung CT showed a reduced tumor size without tumor progression and metastasis ( Figure 1D ).
case_images: Timeline of interventions and outcomes.
case_images: fonc-12-979462-g002.jpg
case_images: PMC9515502_01_fonc-12-979462-g002.jpg
case_images: f2
case_images: The timeline is shown in  Figure 2 .
case_images: Serum levels of laboratory parameters in the patient. (A) Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyltransferase (GGT); (B) total bilirubin (TBil), direct bilirubin (DBil), indirect bilirubin (IBil), and prothrombin time activity (PTA). ULN, upper limit of normal; LLN, lower limit of normal.
case_images: fonc-12-979462-g003.jpg
case_images: PMC9515502_01_fonc-12-979462-g003.jpg
case_images: f3
case_images: The serum levels of the laboratory parameters in the patient are shown in  Figure 3 .